Fluidra (FDR) investor relations material

Opening remarks and agenda

• The meeting opened with acknowledgments to shareholders and staff, emphasizing trust and long-term commitment.

• The agenda included formal requirements, a CEO presentation on 2025 performance, and a Q&A session.

• Shareholders could participate and submit questions both in person and remotely, with procedures outlined for inclusion in the minutes.

Financial performance review

• Sales grew from EUR 1.37 billion in 2019 to EUR 2.18 billion in 2025, a 60% increase.

• Adjusted EBITDA rose by 86% to EUR 501 million, with a margin improvement of over 300 basis points.

• FY 2025 sales increased by 4%, adjusted EBITDA by 5%, and adjusted net profit per share by 8% to EUR 1.30.

• Dividend distributed was EUR 0.60 per share, up 9% from the previous year.

• Q1 2026 sales reached EUR 564 million, with 5% growth at constant currency and a gross margin of 57%.

Board and executive committee updates

• Two board members, Barbara and Steve Langman, were acknowledged for their service; Allison Steiner and Stephen Kaniewski were proposed as new directors.

• The board's role in long-term strategy and oversight was emphasized.